Inflammation as a causative factor in the aetiology of Parkinson's disease

Parkinson's disease (PD) is a progressive neurodegenerative disorder affecting mainly the elderly, although a small proportion of PD patients develop the illness at a much younger age. In the former group, idiopathic PD patients, the causes of the illness have been the subject of longstanding debate with environmental toxins, mitochondrial dysfunction, abnormal protein handling and oxidative stress being suggested. One problem has been that the epidemiology of PD has offered few clues to provide evidence for a single major causative factor. Comparatively recently it has been found that in both patients and experimental models of PD in animals neuroinflammation appears to be a ubiquitous finding. These cases present with all of the classical features of inflammation including phagocyte activation, increased synthesis and release of proinflammatory cytokines and complement activation. Although this process is vital for normal function and protection in both the CNS, as in the periphery, it is postulated that in the aetiology of PD this process may spiral out of control with over activation of microglia, over production of cytokines and other proinflammatory mediators as well as the release of destructive molecules such as reactive oxygen species. Given that dopaminergic neurons in the substantia nigra are relatively vulnerable to ‘stress’ and the region has a large population of microglia in comparison to other CNS structures, these events may easily trigger neurodegeneration. These factors are examined in this review along with a consideration of the possible use of anti‐inflammatory drugs in PD.

[1]  N. Rothwell,et al.  The role of inflammation in CNS injury and disease , 2006, British journal of pharmacology.

[2]  P. Riederer,et al.  Brain beta 2-microglobulin levels are elevated in the striatum in Parkinson's disease. , 1995, Journal of neural transmission. Parkinson's disease and dementia section.

[3]  J. Schulz,et al.  Inhibition of Neuronal Nitric Oxide Synthase by 7‐Nitroindazole Protects Against MPTP‐Induced Neurotoxicity in Mice , 1995, Journal of neurochemistry.

[4]  C. Ferrari,et al.  Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease , 2003, The European journal of neuroscience.

[5]  Hideki Hayakawa,et al.  Caspase-11 Mediates Inflammatory Dopaminergic Cell Death in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson's Disease , 2004, The Journal of Neuroscience.

[6]  B. Liu,et al.  Novel anti-inflammatory therapy for Parkinson's disease. , 2003, Trends in pharmacological sciences.

[7]  Belinda Wilson,et al.  Aggregated α‐synuclein activates microglia: a process leading to disease progression in Parkinson's disease , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  K. Vrana,et al.  Cytotoxic and genotoxic potential of dopamine , 1999, Journal of neuroscience research.

[9]  E. Masliah,et al.  Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease. , 2006, Biochemical and biophysical research communications.

[10]  Bin Liu,et al.  NADPH Oxidase Mediates Lipopolysaccharide-induced Neurotoxicity and Proinflammatory Gene Expression in Activated Microglia* , 2004, Journal of Biological Chemistry.

[11]  Bin Liu,et al.  Microglial activation‐mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease , 2002, Journal of neurochemistry.

[12]  S. Paul,et al.  Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[13]  J. Ghika [Genetics of parkinsonism]. , 2000, Revue medicale de la Suisse romande.

[14]  H. Ahsan,et al.  Oxygen free radicals and systemic autoimmunity , 2003, Clinical and experimental immunology.

[15]  R. Rodnitzky,et al.  Histological and biochemical pathology in a family with autosomal dominant Parkinsonism and dementia , 1993 .

[16]  Andis Klegeris,et al.  Alpha‐synuclein and its disease‐causing mutants induce ICAM‐1 and IL‐6 in human astrocytes and astrocytoma cells , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  S. Minoshima,et al.  Familial Parkinson's disease. Alpha-synuclein and parkin. , 2001, Advances in neurology.

[18]  G. Raivich,et al.  Systemic LPS Injection Leads to Granulocyte Influx into Normal and Injured Brain: Effects of ICAM-1 Deficiency , 2001, Experimental Neurology.

[19]  T. Sherer,et al.  Environment, Mitochondria, and Parkinson's Disease , 2002, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[20]  G. Wilkin,et al.  Inflammatory Regulators in Parkinson's Disease: iNOS, Lipocortin-1, and Cyclooxygenases-1 and -2 , 2000, Molecular and Cellular Neuroscience.

[21]  P. Riederer,et al.  Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients , 1994, Neuroscience Letters.

[22]  D. Graham,et al.  Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. , 1978, Molecular pharmacology.

[23]  P. Mander,et al.  Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration , 2002, Neuroscience.

[24]  S. Kish,et al.  In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining , 1997, Neuroscience.

[25]  T. Nagatsu,et al.  Parkinson's disease: changes in apoptosis-related factors suggesting possible gene therapy , 2002, Journal of Neural Transmission.

[26]  B. Ferger,et al.  Inhibition of the cyclooxygenase isoenzymes COX‐1 and COX‐2 provide neuroprotection in the MPTP‐mouse model of Parkinson's disease , 2001, Synapse.

[27]  M. Hengartner The biochemistry of apoptosis , 2000, Nature.

[28]  B. Liu,et al.  Role of Nitric Oxide in Inflammation‐Mediated Neurodegeneration , 2002, Annals of the New York Academy of Sciences.

[29]  M. Sawada,et al.  Cellular and Molecular Mechanisms of Parkinson’s Disease: Neurotoxins, Causative Genes, and Inflammatory Cytokines , 2006, Cellular and Molecular Neurobiology.

[30]  B. Liu,et al.  Distinct Role for Microglia in Rotenone-Induced Degeneration of Dopaminergic Neurons , 2002, The Journal of Neuroscience.

[31]  K. Barron The microglial cell. A historical review , 1995, Journal of the Neurological Sciences.

[32]  J. Antel,et al.  Glial cell influence on the human blood‐brain barrier , 2001, Glia.

[33]  J. Bart,et al.  Blood–brain barrier dysfunction in parkinsonian midbrain in vivo , 2005, Annals of neurology.

[34]  T. L. Collins,et al.  Adhesion receptors in lymphocyte activation. , 1994, Current opinion in immunology.

[35]  J. Cano,et al.  Dopamine‐dependent neurotoxicity of lipopolysaccharide in substantia nigra , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[36]  L. Adorini,et al.  Regulation of T-cell responses by CNS antigen-presenting cells: different roles for microglia and astrocytes. , 2000, Immunology today.

[37]  Dong-Kug Choi,et al.  Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[38]  A. Lang,et al.  Parkinson's disease. First of two parts. , 1998, The New England journal of medicine.

[39]  J. Schneider-Mergener,et al.  FAN, a Novel WD-Repeat Protein, Couples the p55 TNF-Receptor to Neutral Sphingomyelinase , 1996, Cell.

[40]  J. Miklossy,et al.  Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys , 2006, Experimental Neurology.

[41]  H. Ichinose,et al.  Cytokines in Parkinson's disease. , 2000, Journal of neural transmission. Supplementum.

[42]  A. Schapira,et al.  Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia. , 1999, Biochimica et biophysica acta.

[43]  G. Bing,et al.  Interleukin-10 protects against inflammation-mediated degeneration of dopaminergic neurons in substantia nigra , 2007, Neurobiology of Aging.

[44]  E. Hirsch,et al.  Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease , 1994, Neuroscience Letters.

[45]  H. Vanderstichele,et al.  An in vitro model for the study of microglia-induced neurodegeneration: involvement of nitric oxide and tumor necrosis factor-α , 2001, Neurochemistry International.

[46]  B. Liu,et al.  Dextromethorphan Protects Dopaminergic Neurons against Inflammation-Mediated Degeneration through Inhibition of Microglial Activation , 2003, Journal of Pharmacology and Experimental Therapeutics.

[47]  Zh Feng,et al.  Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl1, 2, 3, 6-tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra , 2002, Neuroscience Letters.

[48]  P. Carvey,et al.  Lipopolysaccharide (LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-α, interleukin-1β, and nitric oxide , 2002 .

[49]  M. Miura,et al.  Neurotoxic Effects of Lipopolysaccharide on Nigral Dopaminergic Neurons Are Mediated by Microglial Activation, Interleukin-1β, and Expression of Caspase-11 in Mice* , 2004, Journal of Biological Chemistry.

[50]  H. Ichinose,et al.  Increase in level of tumor necrosis factor (TNF)-α in 6-hydroxydopamine-lesioned striatum in rats without influence of systemic l-DOPA on the TNF-α induction , 1999, Neuroscience Letters.

[51]  S. Tufik,et al.  Different parkinsonism models produce a time-dependent induction of COX-2 in the substantia nigra of rats , 2006, Brain Research.

[52]  M. Hoehn,et al.  Parkinsonism , 1998, Neurology.

[53]  K. Suk,et al.  Hypoxic induction of caspase-11/caspase-1/interleukin-1beta in brain microglia. , 2003, Brain research. Molecular brain research.

[54]  M. Beal Mitochondria, Oxidative Damage, and Inflammation in Parkinson's Disease , 2003, Annals of the New York Academy of Sciences.

[55]  Georg W. Kreutzberg,et al.  Neuroglial activation repertoire in the injured brain: graded response, molecular mechanisms and cues to physiological function , 1999, Brain Research Reviews.

[56]  Beata Sikorska,et al.  Microglial cells in neurodegenerative disorders. , 2006, Folia neuropathologica.

[57]  B. Liu,et al.  Synergistic Dopaminergic Neurotoxicity of the Pesticide Rotenone and Inflammogen Lipopolysaccharide: Relevance to the Etiology of Parkinson's Disease , 2003, The Journal of Neuroscience.

[58]  P Riederer,et al.  Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. , 1995, Neuroscience letters.

[59]  M. Ross,et al.  N-acetyl-cysteine suppresses amniotic fluid and placenta inflammatory cytokine responses to lipopolysaccharide in rats. , 2006, American journal of obstetrics and gynecology.

[60]  S. Takashima,et al.  Endotoxin, cerebral blood flow, amino acids and brain damage in young rabbits , 1988, Brain and Development.

[61]  D. Loeffler,et al.  Effects of Enhanced Striatal Dopamine Turnover In Vivo on Glutathione Oxidation , 1994, Clinical neuropharmacology.

[62]  Andre Parent,et al.  Presence of reactive microglia in monkey substantia nigra years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine administration , 2003, Annals of neurology.

[63]  J. Langston,et al.  Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine exposure , 1999, Annals of neurology.

[64]  H. Przuntek,et al.  Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease. , 1998, Acta neurologica Scandinavica.

[65]  G. Bing,et al.  Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration , 2003, Neurobiology of Disease.

[66]  D. Perl,et al.  Protein Nitration in Parkinson's Disease , 1998, Journal of neuropathology and experimental neurology.

[67]  J. Xie,et al.  Parkinson's Disease Brain Mitochondrial Complex I Has Oxidatively Damaged Subunits and Is Functionally Impaired and Misassembled , 2006, The Journal of Neuroscience.

[68]  P. Riederer,et al.  Brain β2-microglobulin levels are elevated in the striatum in Parkinson's diseaselevels are elevated in the striatum in Parkinson's disease , 1995 .

[69]  W. Le,et al.  Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum , 2001, Brain Research.

[70]  M. Block,et al.  Microglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism , 2005, Progress in Neurobiology.

[71]  H. Przuntek,et al.  Short communication Interleukin‐6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease , 1998, Acta neurologica Scandinavica.

[72]  D. Reif,et al.  Nitric oxide mediates iron release from ferritin. , 1990, Archives of biochemistry and biophysics.

[73]  K. Mohanakumar,et al.  Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats , 2003, Brain Research.

[74]  T. J. Cunningham,et al.  Differential immunochemical markers reveal the normal distribution of brain macrophages and microglia in the developing rat brain , 1991, The Journal of comparative neurology.

[75]  E. Esposito,et al.  Aspirin protects striatal dopaminergic neurons from neurotoxin-induced degeneration: An in vivo microdialysis study , 2006, Brain Research.

[76]  D. Tse,et al.  Potential oxidative pathways of brain catecholamines. , 1976, Journal of medicinal chemistry.

[77]  L. Zon,et al.  Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis , 1996, Nature.

[78]  Andreas Hald,et al.  Oxidative stress and inflammation in Parkinson's disease: is there a causal link? , 2005, Experimental Neurology.

[79]  D. Miller,et al.  Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: Implications for Parkinson's disease , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[80]  K. Tanaka,et al.  Increase in level of tumor necrosis factor (TNF)-alpha in 6-hydroxydopamine-lesioned striatum in rats without influence of systemic L-DOPA on the TNF-alpha induction. , 1999, Neuroscience letters.

[81]  J. Dichgans,et al.  Deficiency of Inducible Nitric Oxide Synthase Protects Against MPTP Toxicity In Vivo , 2000, Journal of neurochemistry.

[82]  R. Flavell,et al.  Apoptosis. Death of a monopoly? , 2001, Science.

[83]  W. Le,et al.  Antibodies from patients with Parkinson's disease react with protein modified by dopamine oxidation , 1998, Journal of neuroscience research.

[84]  Pathogenic role of glial cells in Parkinson's disease , 2003, Movement disorders : official journal of the Movement Disorder Society.

[85]  Peter Riederer,et al.  Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients , 1995, Neuroscience Letters.

[86]  Barry Halliwell,et al.  Oxidative stress and neurodegeneration: where are we now? , 2006, Journal of neurochemistry.

[87]  H. Okano,et al.  Caspase-mediated oligodendrocyte cell death in the pathogenesis of autoimmune demyelination , 2003, Neuroscience Research.

[88]  J. Cano,et al.  Lipopolysaccharide Intranigral Injection Induces Inflammatory Reaction and Damage in Nigrostriatal Dopaminergic System , 1998, Journal of neurochemistry.

[89]  Robert M Friedlander,et al.  Apoptosis and caspases in neurodegenerative diseases. , 2003, The New England journal of medicine.

[90]  A. Leviton,et al.  Does prepregnancy bacterial vaginosis increase a mother's risk of having a preterm infant with cerebral palsy? , 1997, Developmental medicine and child neurology.

[91]  J S Beckman,et al.  Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. , 1992, Archives of biochemistry and biophysics.

[92]  R. Mohney,et al.  Regional Difference in Susceptibility to Lipopolysaccharide-Induced Neurotoxicity in the Rat Brain: Role of Microglia , 2000, The Journal of Neuroscience.

[93]  S. Daniel,et al.  Glial pathology but absence of apoptotic nigral neurons in long‐standing Parkinson's disease , 1998, Movement disorders : official journal of the Movement Disorder Society.

[94]  E. Joe,et al.  Gangliosides activate microglia via protein kinase C and NADPH oxidase , 2004, Glia.

[95]  N. Rothwell,et al.  Cytokines and acute neurodegeneration , 1997, Molecular Psychiatry.

[96]  S. Rivest,et al.  Circulating cell wall components derived from gram‐negative, not gram‐positive, bacteria cause a profound induction of the gene‐encoding Toll‐like receptor 2 in the CNS , 2001, Journal of neurochemistry.

[97]  N. Cooper,et al.  The C5a complement activation peptide increases IL-1β and IL-6 release from amyloid-β primed human monocytes: implications for Alzheimer’s disease , 2000, Journal of Neuroimmunology.

[98]  J. Cano,et al.  Minocycline reduces the lipopolysaccharide-induced inflammatory reaction, peroxynitrite-mediated nitration of proteins, disruption of the blood–brain barrier, and damage in the nigral dopaminergic system , 2004, Neurobiology of Disease.

[99]  Shuxian Hu,et al.  Nitric oxide production and neurotoxicity mediated by activated microglia from human versus mouse brain. , 1994, The Journal of infectious diseases.

[100]  H. Neumann Control of glial immune function by neurons , 2001, Glia.

[101]  P. Mcgeer,et al.  Inflammation and neurodegeneration in Parkinson's disease. , 2004, Parkinsonism & related disorders.

[102]  Todd B. Sherer,et al.  Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.

[103]  D. Bonifati,et al.  Role of complement in neurodegeneration and neuroinflammation. , 2007, Molecular immunology.

[104]  D. Clarke,et al.  A Role for Tumor Necrosis Factor α in Death of Dopaminergic Neurons Following Neural Transplantation , 2002, Experimental Neurology.

[105]  B. Babior Phagocytes and oxidative stress. , 2000, The American journal of medicine.

[106]  Y. Mizuno,et al.  Inflammation and infection in Parkinson's disease. , 2006, Histology and histopathology.

[107]  M. Shin,et al.  Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[108]  H. Ichinose,et al.  Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from Parkinsonian brain , 2000, Journal of Neural Transmission.

[109]  P. Mcgeer,et al.  Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins , 2004, Acta Neuropathologica.

[110]  W. Willett,et al.  Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. , 2003, Archives of neurology.

[111]  P. Ruppel,et al.  Competitive irreversible inhibition of dopamine uptake by 6-hydroxydopamine. , 1993, Research communications in chemical pathology and pharmacology.

[112]  Timothy A. Springer,et al.  Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1) , 1987, Cell.

[113]  E. Hirsch,et al.  The inflammatory response in the Parkinson brain , 2001, Clinical Neuroscience Research.

[114]  K. Wakabayashi,et al.  The cellular pathology of Parkinson's disease , 2001, Neuropathology (Kyoto. 1993).

[115]  Y. Hannun,et al.  Programmed cell death induced by ceramide. , 1993, Science.

[116]  B. Jeune,et al.  Few microorganisms associated with bacterial vaginosis may constitute the pathologic core: a population-based microbiologic study among 3596 pregnant women. , 1998, American journal of obstetrics and gynecology.

[117]  P. Carvey,et al.  Progressive dopamine neuron loss following supra-nigral lipopolysaccharide (LPS) infusion into rats exposed to LPS prenatally , 2006, Experimental Neurology.

[118]  P. Carvey,et al.  In utero bacterial endotoxin exposure causes loss of tyrosine hydroxylase neurons in the postnatal rat midbrain , 2002, Movement disorders : official journal of the Movement Disorder Society.

[119]  P. Mcgeer,et al.  Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.

[120]  F. Aloisi Immune function of microglia , 2001, Glia.

[121]  S. Pennathur,et al.  Mass Spectrometric Quantification of 3-Nitrotyrosine, ortho-Tyrosine, and o,o′-Dityrosine in Brain Tissue of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated Mice, a Model of Oxidative Stress in Parkinson's Disease* , 1999, The Journal of Biological Chemistry.

[122]  R. Flavell,et al.  Death of a Monopoly? , 2001, Science.

[123]  Wenjie Xie,et al.  Microglial Activation and Dopaminergic Cell Injury: An In Vitro Model Relevant to Parkinson's Disease , 2001, The Journal of Neuroscience.

[124]  O. Isacson,et al.  Neuroinflammation of the nigrostriatal pathway during progressive 6‐OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging , 2002, The European journal of neuroscience.

[125]  P. Jenner,et al.  The acute and the long‐term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation , 2005, The European journal of neuroscience.

[126]  P. Jenner Parkinson's disease, pesticides and mitochondrial dysfunction , 2001, Trends in Neurosciences.

[127]  R. Testi,et al.  Sphingomyelin breakdown and cell fate. , 1996, Trends in biochemical sciences.

[128]  S. Lee,et al.  Tetrahydrobiopterin causes mitochondrial dysfunction in dopaminergic cells: Implications for Parkinson's disease , 2006, Neurochemistry International.

[129]  Wei Zhang,et al.  The role of microglia in paraquat-induced dopaminergic neurotoxicity. , 2005, Antioxidants & redox signaling.

[130]  J. Cano,et al.  The Single Intranigral Injection of LPS as a New Model for Studying the Selective Effects of Inflammatory Reactions on Dopaminergic System , 2000, Neurobiology of Disease.

[131]  George Kollias,et al.  Uncoupling the Proinflammatory from the Immunosuppressive Properties of Tumor Necrosis Factor (Tnf) at the P55 TNF Receptor Level , 2001, The Journal of experimental medicine.

[132]  A. Schapira,et al.  Evidence for mitochondrial dysfunction in Parkinson's disease—a critical appraisal , 2004, Movement disorders : official journal of the Movement Disorder Society.

[133]  A. Członkowska,et al.  The Inflammatory Reaction Following 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Intoxication in Mouse , 1999, Experimental Neurology.

[134]  M. Schwartz,et al.  Increased post-traumatic survival of neurons in IL-6-knockout mice on a background of EAE susceptibility , 2001, Journal of Neuroimmunology.

[135]  G. Kreutzberg Microglia: a sensor for pathological events in the CNS , 1996, Trends in Neurosciences.

[136]  Haruhiko Akiyama,et al.  Rate of cell death in parkinsonism indicates active neuropathological process , 1988, Annals of neurology.

[137]  S. Rivest,et al.  Regulation of the Genes Encoding Interleukin‐6, Its Receptor, and gp130 in the Rat Brain in Response to the Immune Activator Lipopolysaccharide and the Proinflammatory Cytokine Interleukin‐1β , 1997, Journal of neurochemistry.

[138]  Erzsebet Kokovay,et al.  Bone marrow-derived microglia contribute to the neuroinflammatory response and express iNOS in the MPTP mouse model of Parkinson's disease , 2005, Neurobiology of Disease.

[139]  H. Wekerle,et al.  Neuronal Control of the Immune Response in the Central Nervous System: Linking Brain Immunity to Neurodegeneration , 1998, Journal of neuropathology and experimental neurology.

[140]  T. Dawson,et al.  Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[141]  Stephanie B. Conant,et al.  Complement activation in the Parkinson's disease substantia nigra: an immunocytochemical study , 2006, Journal of Neuroinflammation.

[142]  R. Rosenberg Mitochondrial therapy for Parkinson disease. , 2002, Archives of neurology.

[143]  T. Montine,et al.  Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. , 1999, The American journal of pathology.

[144]  Joseph K. H. Ma,et al.  THE DUAL EFFECT OF THE PARTICULATE AND ORGANIC COMPONENTS OF DIESEL EXHAUST PARTICLES ON THE ALTERATION OF PULMONARY IMMUNE/INFLAMMATORY RESPONSES AND METABOLIC ENZYMES , 2002, Journal of environmental science and health. Part C, Environmental carcinogenesis & ecotoxicology reviews.

[145]  B. Engelhardt,et al.  Intracellular Domain of Brain Endothelial Intercellular Adhesion Molecule-1 Is Essential for T Lymphocyte-Mediated Signaling and Migration1 , 2003, The Journal of Immunology.

[146]  U. Gimsa,et al.  Phagocytosis of neuronal or glial debris by microglial cells: Upregulation of MHC class II expression and multinuclear giant cell formation in vitro , 2000, Glia.

[147]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[148]  G. Deuschl,et al.  Activation of microglia by human neuromelanin is NF‐κB‐dependent and involves p38 mitogen‐activated protein kinase: implications for Parkinson's disease , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[149]  H. Rus,et al.  The complement system in central nervous system diseases , 2001, Immunologic research.

[150]  S. Mandel,et al.  Using cDNA microarray to assess Parkinson's disease models and the effects of neuroprotective drugs. , 2003, Trends in pharmacological sciences.

[151]  Jos Prickaerts,et al.  Modeling Parkinson's Disease in Rats: An Evaluation of 6-OHDA Lesions of the Nigrostriatal Pathway , 2002, Experimental Neurology.

[152]  G. Halliday,et al.  An inflammatory review of Parkinson’s disease , 2002, Progress in Neurobiology.

[153]  J. Bonnefoy,et al.  A new role for CD23 in inflammation. , 1996, Immunology today.

[154]  K. Lim,et al.  The Cast of Molecular Characters in Parkinson's Disease , 2003, Annals of the New York Academy of Sciences.

[155]  Y. Glinka,et al.  Dopamine Neurotoxicity: Inhibition of Mitochondrial Respiration , 1995, Journal of neurochemistry.

[156]  E. Hirsch,et al.  FcεRII/CD23 Is Expressed in Parkinson’s Disease and Induces, In Vitro, Production of Nitric Oxide and Tumor Necrosis Factor-α in Glial Cells , 1999, The Journal of Neuroscience.

[157]  C. Carter,et al.  Aspirin and Salicylate Protect Against MPTP‐Induced Dopamine Depletion in Mice , 1998, Journal of neurochemistry.

[158]  A. Członkowska,et al.  Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinson's disease mice model. , 1996, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[159]  Ted M. Dawson,et al.  Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease , 1999, Nature Medicine.

[160]  P. Södersten,et al.  Increased cerebrospinal fluid concentration of nitrite in Parkinson's disease , 1995, Neuroreport.

[161]  I. Pérez-Otaño,et al.  Glia-dependent neurotoxicity and neuroprotection in mesencephalic cultures , 1995, Brain Research.

[162]  J. Cano,et al.  The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh‐TNF‐α, IL‐1β and IFN‐γ , 2002 .

[163]  F. Fan,et al.  Redox regulation of glial inflammatory response to lipopolysaccharide and interferonγ , 2004, Journal of neuroscience research.

[164]  M. Vila,et al.  NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[165]  M. Moskowitz,et al.  Dual Role of Caspase-11 in Mediating Activation of Caspase-1 and Caspase-3 under Pathological Conditions , 2000, The Journal of cell biology.

[166]  P. Riederer,et al.  Oxidative stress: free radical production in neural degeneration. , 1994, Pharmacology & therapeutics.

[167]  B. Liu,et al.  Synergistic dopaminergic neurotoxicity of MPTP and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[168]  J. Cano,et al.  Inflammatory process as a determinant factor for the degeneration of substantia nigra dopaminergic neurons , 2004, Journal of Neural Transmission.

[169]  P. Carvey,et al.  6‐Hydroxydopamine‐induced alterations in blood–brain barrier permeability , 2005, The European journal of neuroscience.

[170]  Dong-Kug Choi,et al.  Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease , 2002, The Journal of Neuroscience.

[171]  S. Mohand-Said,et al.  Neurodegenerative and Neuroprotective Effects of Tumor Necrosis Factor (TNF) in Retinal Ischemia: Opposite Roles of TNF Receptor 1 and TNF Receptor 2 , 2002, The Journal of Neuroscience.

[172]  Y. Agid,et al.  Nitric oxide synthase and neuronal vulnerability in parkinson's disease , 1996, Neuroscience.

[173]  J. O'Callaghan,et al.  Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor‐α , 2006, Journal of neurochemistry.

[174]  G. Cohen,et al.  Coupling of Dopamine Oxidation (Monoamine Oxidase Activity) to Glutathione Oxidation Via the Generation of Hydrogen Peroxide in Rat Brain Homogenates , 1981, Journal of neurochemistry.

[175]  J. Obeso,et al.  Dopamine Cell Degeneration Induced by Intraventricular Administration of 6-Hydroxydopamine in the Rat: Similarities with Cell Loss in Parkinson's Disease , 2001, Experimental Neurology.

[176]  P. Mcgeer,et al.  Inflammation in Parkinson's disease. , 2001, Advances in neurology.

[177]  S. Rivest,et al.  Bone marrow stem cells have the ability to populate the entire central nervous system into fully differentiated parenchymal microglia , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[178]  P. Damier,et al.  Glial cells and inflammation in parkinson's disease: A role in neurodegeneration? , 1998, Annals of neurology.

[179]  C. Tanner Is the cause of Parkinson's disease environmental or hereditary? Evidence from twin studies. , 2003, Advances in neurology.